- Guide to PHARMACOLOGY
Synonyms: DCC-270 | DCC-2701 | DP-5164
Compound class: Synthetic organic
Comment: Altiratinib is an oral, selective and potent inhibitor of MET, TIE2, VEGFR2 and TRK kinases, being investigated for its potential anticancer activity. This specific compound is claimed in patent WO2016061231 , and prior patent submissions.
A drug repurposing screen has identified altiratinib as a potential antiprotozoal agent . The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|The US FDA has granted altiratinib Orphan Drug Designation for glioblastoma multiforme (GBM). Phase 1 clinical trial NCT02228811, which was designed to evaluate oral altiratinib monotherapy vs. various locally advanced and metastatic solid tumours was terminated.|
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT02228811||A Study of DCC-2701 in Participants With Advanced Solid Tumors||Phase 1 Interventional||Deciphera Pharmaceuticals LLC|